Humana Inc. Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Health Care Providers and Services | Market Cap: ₹37.1K Cr
- Membership growth trajectory is on track, with dynamic management of distribution and growth if needed (Page 2). - Humana expects to double individual Medicare Advantage (MA) margins in 2026, adjusted for Stars performance.
From Humana Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹308.7
Market Cap
₹37.1K Cr
P/E Ratio
32.2
Revenue Rank
Margin Rank
How does Humana Inc. rank in Health Care Providers and Services?
Compare Humana Inc. against every Health Care Providers and Services company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 3- →Membership growth trajectory is on track, with dynamic management of distribution and growth if needed (Page 2).
- →Solid growth across CenterWell's lines of business: pharmacy, primary care (including recent Max Health acquisition), and home health (Page 6).
- →Expansion of CenterWell’s reach into new critical markets through acquisitions like Max Health (Page 2, 6).
- →Continued Medicaid membership growth (~50,000 lives) from new program starts in Michigan, Illinois, and South Carolina (Page 2).
- →Anticipated doubling of individual Medicare Advantage (MA) margin in 2026, reflecting improved operational performance and pricing discipline (Page 2).
- →Stable and compelling MA margin expected, unlocking earnings potential by 2028 (Page 3).
- →Growth expected from diversified business lines beyond benefits, supported by mature transformation efforts (Page 12).
- →Emphasis on retention and quality improvements to support sustainable long-term growth (Page 5).
📈 Profitability & Margins
Rank 3- →Humana expects to double individual Medicare Advantage (MA) margins in 2026, adjusted for Stars performance.
- →Focus is on returning to a sustainable margin of at least 3% by 2028, with progress to be made in 2027.
- →Pricing discipline and tight cost management, including operating cost reductions and tactical/strategic measures, support margin improvement.
- →Operating leverage continues to be a meaningful contributor to earnings growth through 2028.
- →Membership growth trajectory remains on track, which supports stable and compelling MA margins.
- →Capital allocation includes strategic acquisitions (e.g., Max Health) and noncore asset divestitures to fund growth.
- →Guidance for 2026 PDP (Prescription Drug Plan) business remains in line with expectations, supporting overall earnings stability.
- →Management remains cautious but confident in navigating bids and benefit adjustments to meet long-term earnings targets.
🏗️ Capital Expenditure Plans
Yes- →Humana is pursuing noncore asset divestitures to help fund strategic acquisitions and expects to share more news on this in the coming months. (Page 3)
- →They have executed initiatives to optimize the balance sheet, including subsidiary reinsurance and legal entity restructuring, mitigating over $3 billion in capital contribution requirements for 2026. (Page 3)
- →Issued $1 billion junior subordinated notes in March, expected to fund 2027 maturities, indicating capital management and funding for future investments. (Page 3)
- →Continuing to evaluate a pipeline of initiatives to further strengthen the balance sheet, supporting ongoing and future strategic investments. (Page 3)
💰 Fundraising & Capital Structure
Yes- →Humana is maintaining dividend levels and limiting share repurchases to offset employee stock compensation dilution.
- →They intend to increase dividends and share repurchases when cash flows and funding capacity grow with the execution of their plan.
- →The company is pursuing noncore asset divestitures to help fund strategic acquisitions, with more updates expected in the coming months.
- →Recent initiatives include issuing $1 billion junior subordinated notes in March to fund 2027 maturities.
- →Additional efforts to optimize the balance sheet involve subsidiary reinsurance and augmenting legal entity structures, mitigating over $3 billion in capital contribution requirements for 2026.
- →Any potential cash obligations related to partner Welsh Carson's put options (around $1 billion to $1.5 billion in 2027) are included in Humana's funding plan.
- →Overall, Humana is actively managing debt and equity strategies but no immediate equity issuance is mentioned explicitly.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Health Care Providers and Services this season
- BrightSpring Health Services, Inc. (Q2 FY26)
BrightSpring Health Services, Inc. Q2 FY26 quarterly results analysis. Pharmacy Solutions expected to see balanced sequential revenue and EBITDA growth througho
- DaVita Inc. (Q2 FY26)
DaVita Inc. Q2 FY26 quarterly results analysis. Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying pe
- Tenet Healthcare Corporation (Q2 FY26)
Tenet Healthcare Corporation Q2 FY26 quarterly results analysis. Hospital segment expects a 10% normalized year-over-year adjusted EBITDA growth in 2026, suppor
- Guardant Health, Inc. (Q2 FY26)
Guardant Health, Inc. Q2 FY26 quarterly results analysis. Sales team started this year with ~300 reps; incremental gross profit will be reinvested in expanding
Frequently Asked Questions
What were Humana Inc. Q2 FY26 results?
- Membership growth trajectory is on track, with dynamic management of distribution and growth if needed (Page 2). - Humana expects to double individual Medicare Advantage (MA) margins in 2026, adjusted for Stars performance.
What is Humana Inc. share price analysis?
Humana Inc. currently shows a below-average growth signal. The stock trades at a P/E of 32.2 with a market cap of $37,063. Investors should review the full earnings analysis for detailed insights.
Is Humana Inc. planning capital expenditure?
- Humana is pursuing noncore asset divestitures to help fund strategic acquisitions and expects to share more news on this in the coming months.
Keep Humana Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.